Barclays Boosts Arvinas (NASDAQ: ARVN) Price Target on FDA Approval and Strategic Partnership

Font: Financial Modeling Prep  • May 13, 2026

• Analyst Confidence: Barclays has raised its price target for Arvinas (NASDAQ: ARVN) to $20.00, signaling strong analyst confidence in the biotechnology company's future prospects.
• Groundbreaking FDA Approval: Arvinas secured U.S. Food and Drug Administration (FDA) approval for VEPPANU, marking it as the first-ever approved PROTAC protein degrader and validating the company's innovative scientific approach.
• Strategic Commercialization Deal: A global licensing agreement with Pfizer and Rigel Pharmaceuticals for VEPPANU's commercialization provides Arvinas with $85 million in upfront payments and potential milestone payments up to $320 million, enabling focus on its next-generation drug pipeline.

Barclays has increased its price target for Arvinas (NASDAQ: ARVN) to $20.00, a raise from its previous $18.00 target. Arvinas is a leading biotechnology company that develops innovative treatments using a technology called targeted protein degradation. At the time of the update, Arvinas stock was trading at $9.57, representing a potential 91% upside to the new target.

This analyst upgrade follows significant news from the company. Arvinas recently received U.S. Food and Drug Administration (FDA) approval for its drug, VEPPANU. As highlighted by GlobeNewswire, this drug is the first-ever approved PROTAC protein degrader, a new class of medicine, validating the company's scientific approach to drug development.

VEPPANU is a treatment for adults with a specific type of advanced or metastatic breast cancer. To help bring the drug to patients, Arvinas and its partner Pfizer have entered into a global licensing agreement with Rigel Pharmaceuticals. Rigel will now manage the commercialization, development, and manufacturing of VEPPANU.

The deal provides Arvinas and Pfizer with $85 million in upfront and transition payments. The agreement also includes the potential for an additional $320 million in milestone payments and tiered royalties on future net sales. Royalties are a percentage of sales paid to the drug's owner.

This transaction allows Arvinas to redirect its own money toward developing its next generation of drugs. The company is focusing its pipeline on new treatments for oncology, neurodegenerative disorders, and neuromuscular diseases. This strategy aims to build on the success of its protein degradation platform.